Your session is about to expire
← Back to Search
Combined Radiation + Chemotherapy for Pancreatic Cancer
Phase 2
Waitlist Available
Research Sponsored by Goshen Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
- Disease that has progressed after prior treatment
Histologically or cytologically confirmed pancreatic cancer with liver metastases
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial will give radiation therapy in different ways and give it together with chemotherapy to see if it kills more tumor cells in patients with pancreatic cancer and liver metastases.
Who is the study for?
This trial is for patients with new or returning pancreatic cancer that has spread to the liver and can't be removed by surgery. Participants should have a good performance status, meaning they're able to carry out everyday activities well, expect to live more than 3 months, have adequate blood counts and organ function, and not be pregnant. Those who've had previous radiation therapy to the liver or pancreas cannot join.Check my eligibility
What is being tested?
The study tests combining internal radiation using Y-90 microspheres with external tomotherapy radiation alongside chemotherapy drug fluorouracil. The goal is to see if this combination better targets tumor cells while sparing healthy tissue in patients with pancreatic cancer that has spread to the liver.See study design
What are the potential side effects?
Potential side effects include damage to normal tissues near the treated area, fatigue from radiation therapy, and common chemotherapy-related issues like nausea, mouth sores, low blood cell counts increasing infection risk, bleeding problems due to low platelets, and potential kidney impact.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My condition worsened after previous treatment.
Select...
My pancreatic cancer has spread to my liver.
Select...
My cancer is only in my liver and I am receiving targeted radiation therapy.
Select...
I am mostly self-sufficient and active.
Select...
I do not have widespread cancer spread in my abdomen.
Select...
My cancer has worsened after pancreas surgery.
Select...
My condition has been recently diagnosed and I haven't received any treatment yet.
Select...
My cancer has not spread to my brain.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Hepatic and systemic toxicity
Tumor response
Secondary outcome measures
Survival
Time to progression
Find a Location
Who is running the clinical trial?
Goshen Health SystemLead Sponsor
2 Previous Clinical Trials
35 Total Patients Enrolled
Kenneth L. Pennington, MDStudy ChairGoshen Health System
1 Previous Clinical Trials
20 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My condition worsened after previous treatment.My pancreatic cancer has spread to my liver.My cancer is only in my liver and I am receiving targeted radiation therapy.You are expected to live for more than 3 months.I am mostly self-sufficient and active.I have had radiation therapy to my liver or pancreas area before.I do not have widespread cancer spread in my abdomen.My cancer has worsened after pancreas surgery.My condition cannot be treated with surgery.My condition has been recently diagnosed and I haven't received any treatment yet.Your albumin level in the blood is higher than 2 grams per deciliter.You need to have a hemoglobin level of at least 9 grams per deciliter.My cancer has not spread to my brain.Your creatinine level in your blood is less than 2 mg/dL.Your bilirubin level should be less than 2 mg/dL, and you should not have a blockage in your bile ducts.Your white blood cell count is at least 1,500 per cubic millimeter.Your platelet count is at least 100,000 per cubic millimeter.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does this procedure have the approval of the Food and Drug Administration?
"The safety of this medication was estimated to be a 2, as there is some evidence for it being safe but no proof yet that the treatment will have any efficacy."
Answered by AI
Are there any remaining slots for people to join this clinical investigation?
"According to clinicaltrials.gov, this medical investigation is not presently recruiting participants; it was first posted November 1st 2006 and last updated December 18th 2013. Nevertheless, 856 other studies are actively seeking individuals at the moment."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger